anti-CD138

Anti-CD138 refers to a class of monoclonal antibodies or antibody-based agents that specifically target Syndecan-1 (CD138), a cell surface proteoglycan that is a hallmark marker for normal and malignant plasma cells. In the context of diagnostic and translational research, anti-CD138 antibodies are utilized as capture reagents in platforms such as CellSearch (developed by Menarini Silicon Biosystems) to enrich and isolate circulating multiple myeloma cells (CMMCs) from peripheral blood. This application facilitates liquid biopsy monitoring of disease burden and genomic heterogeneity in multiple myeloma patients. Beyond its diagnostic utility, CD138 is a significant therapeutic target, with various anti-CD138 modalities including antibody-drug conjugates (ADCs) and CAR-T cell therapies being investigated for the treatment of plasma cell dyscrasias.

Other names

anti-Syndecan-1 antibodyanti-Syndecan1 antibodyanti-Syndecan 1 antibodyCD138 antibodyCD-138 antibodyCD 138 antibody